NAD+ safety in the research literature, read straight.

The short version

On NAD+ safety, the evidence splits cleanly by route. Oral precursors (NMN and NR — building blocks the body converts into NAD+) were generally well tolerated in randomized trials, with no significant difference in side effects from placebo at the doses tested ^[4][3]. The injectable side is different: IV NAD+ is a compounded, unapproved therapy with little controlled evidence, infused NAD+ leaves the blood within hours, and a compounded NAD+ injection was subject to an FDA Class I recall for endotoxin contamination. This page summarizes the safety record. It is not medical advice and recommends no product or dose.

Reported tolerability and side effects in studies

In controlled oral trials, NAD+ precursors were well tolerated. The 8-week NR study at 100-1000 mg/day reported no flushing, no elevation of LDL cholesterol, no disruption of one-carbon metabolism, and no significant adverse-event difference from placebo at any dose ^[4]. The NMN dose-ranging trial (300-900 mg/day for 60 days) reported no safety issues at any dose ^[3]. The 10-week NMN insulin-sensitivity study likewise reported the intervention as safe over its duration ^[8].

Reported effects on the injectable side are different in character. IV-infusion accounts describe flushing, nausea, and chest or abdominal discomfort that are tied to infusion rate — run too fast, the infusion is less comfortable. Those effects are described as transient. By contrast, the oral-precursor trials simply did not separate from placebo on adverse events at the doses studied ^[4][3]. The most important tolerability variable in this literature is route and rate, not the molecule alone.

How long do NAD side effects last?

Reported IV-infusion effects — flushing, nausea, chest or abdominal discomfort — are tied to infusion rate and are described as transient. In the oral-precursor trials there was no significant adverse-event difference from placebo at the doses tested ^[4][3].

NAD injection and IV NAD+ in the literature

An NAD injection or IV infusion delivers NAD+ parenterally in wellness and clinical settings. It is a compounded, unapproved therapy, and the published evidence behind it is the weakest in this field — mostly pilot or pharmacokinetic work rather than large randomized trials. Pharmacologically, the route faces an inherent problem: infused NAD+ is rapidly cleared from plasma, with near-complete removal within roughly the first two hours of infusion in one pilot study ^[13], and extracellular NAD+ is enzymatically degraded before cellular uptake ^[13].

NAD IV therapy: evidence and quality risks

Controlled evidence for NAD IV therapy is limited. Beyond the efficacy gap, there is a documented quality risk: the FDA issued a Class I recall — its most serious category — of a compounded NAD+ injection for elevated bacterial endotoxin. Compounded injectables are not FDA-approved products, and purity and sterility are not guaranteed across compounders. Reconstituted injectable NAD+ should be kept cold and protected from light, and infusion-rate effects (flushing, nausea, discomfort) are reported when sessions run too fast.

Regulatory and supplement status

NAD+ is not an FDA-approved drug. It is marketed as a dietary supplement, and as a compounded injectable in wellness settings. Several facts belong in any honest safety read:

• NMN's supplement status is contested. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug. This is a marketplace dispute over classification — present it as that, not as "NMN is banned or illegal."
• Compounded IV NAD+ carries documented quality risk. The Class I endotoxin recall is the concrete example; compounded injectables are unapproved and vary by compounder.
• Supplement-grade purity varies. Actual content and purity differ across products, and third-party testing is not guaranteed.
• A cancer-context caution exists. NAD+ supports proliferating cells, and a theoretical concern is that boosting it could fuel existing cancers; NAD+ in oncology has dual, context-dependent roles, so caution is noted for cancer populations ^[5].
• WADA: NAD+ and its precursors (NMN, NR, nicotinamide) are not prohibited by WADA.

What is the downside of taking NAD+?

Oral NAD+ is poorly absorbed intact, so precursors are the studied oral route. The 2025 Nature Metabolism review found human efficacy for hard clinical endpoints remains preliminary ^[7], and compounded IV NAD+ carries contamination risk — an FDA Class I endotoxin recall has been issued.

Is it safe to take NAD daily?

In controlled trials, oral precursors raised blood NAD+ over weeks of daily dosing with no significant adverse-event difference from placebo at the doses tested ^[4][3]. This describes study findings, not a recommendation to take any product.